A new pain relief method that minimizes addiction risks
A peripherally restricted MOR agonist for effective pain management with reduced risks
This study is testing a new pain relief medication that aims to help people with moderate to severe pain without causing the side effects often linked to traditional opioids, making it a safer option for those in need.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abalone Bio, INC. NIH-funded |
| Lab location | 1 site (Emeryville, UNITED STATES) |
| Project ID | NIH-10922509 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of pain relief medication that targets the mu opioid receptor (MOR) without affecting the central nervous system, which is responsible for many side effects associated with traditional opioids. By using a unique technology called Functional Antibody Selection Technology (FAST), the researchers aim to create a peripheral agonist that can effectively manage pain while reducing the risks of addiction and other harmful side effects. This approach seeks to provide a safer alternative for patients suffering from moderate to severe pain.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing moderate to severe pain who are at risk of opioid addiction or are seeking alternatives to traditional opioid medications.
Not a fit: Patients who do not experience pain or those who are not suitable for pain management therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a safer pain management option that alleviates pain without the risks of addiction and severe side effects associated with current opioid treatments.
How similar studies have performed: Previous research has shown promise in developing peripheral agonists for pain relief, indicating that this approach may be viable and could lead to significant advancements in pain management.
Where this research is happening
Emeryville, UNITED STATES
- Abalone Bio, INC. — Emeryville, United States (Active)
Researchers
- Principal investigator: Takeuchi, Toshihiko — Abalone Bio, INC.
- Study coordinator: Takeuchi, Toshihiko
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.